AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.
AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.
The new Apollo Therapeutics Fund will support academic science from Imperial College London, University College London and the University of Cambridge – with the three establishments also contributing a further £3
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
The sector is continuing to show resilience despite financial and market challenges.
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
